07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

Micromet, Bayer preclinical data

In mouse xenograft models of prostate cancer, daily 0.05, 0.5 and 5 mg/kg IV MT112/BAY 2010112 significantly reduced mean tumor volume vs. vehicle-treated controls at day 16 (p<0.001 for all). Data were presented at the...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Micromet, Bayer deal

Micromet will receive a €2.5 million ($3.5 million) milestone payment from Bayer's Bayer Schering Pharma AG subsidiary under a 2009 deal in which Bayer exercised an option to co-develop and commercialize MT112 / BAY 2010112...